Diana Ernst, RPh, Author at MPR

Diana Ernst, RPh

All articles by Diana Ernst, RPh

Suvorexant Evaluated for Insomnia in Patients With Alzheimer Disease Dementia

Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the 2019 American Academy of Neurology Annual Meeting. The phase 3 placebo-controlled trial included 277 patients who were randomized to receive either suvorexant 10mg (which could…

Kadcyla Approved as Adjuvant Treatment for HER2-Positive Early Breast Cancer

The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. The approval was supported by data from the phase 3 KATHERINE study which evaluated the safety and efficacy of Kadcyla vs…

Tibsovo Approved to Treat Newly Diagnosed AML With IDH1 Mutation

The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.